-
NZ boxer Parker promises ring return after doping ban 'lifted'
-
Reusser holds lead as Vollering wins in Tour de France hills
-
Disney profits top estimates on strength in theme park business
-
Argentina's Albornoz hit with four-game ban for 'intimidatory' referee abuse
-
LIV Golf CEO says funding secured to play beyond 2026
-
Guatemala volcano eruption eases off, but alert remains in place
-
Stocks stall tracking earnings, oil dips on Iran-Oman Hormuz move
-
Baby hippo descended from Escobar's herd rescued in Colombia
-
Tuipulotu to lead New Zealand in South African tour opener
-
Woman arrested after four men stabbed in central London
-
Leftist Democrat urges unity after victory in Michigan
-
Celtic boss O'Neill in hospital after 'small procedure'
-
Austria, Slovakia hit new temperature records
-
Israeli forces raid Palestinian refugee camp near Jerusalem
-
Where mountain lions roam, fewer deer in the headlights
-
Explosive drone found near Ukrainian plane at German airport
-
Alonso hails 'emotional' Mudryk return in 1-0 loss to Juventus
-
Leftist Democrat wins stunning primary victory in crucial Michigan
-
Embattled FIFA chief Infantino in emergency talks, suffers Figo blow
-
Inter Milan and AC Milan battle to 1-1 draw in Perth friendly
-
Mudryk back for Chelsea in friendly defeat to Juventus
-
Butterflies seek new habitats as climate changes: study
-
Alarm as explosive drone found near Ukrainian plane at German airport
-
'Deceitful' Infantino 'must go' says Luis Figo
-
Infantino and the failed deal affair -- What they said
-
ヌーシャ・オーベル:彼女はポツダムの抱える問題に対処できるのか?
-
नूशा ऑबेल: क्या वह पॉट्सडैम की समस्याओं से निपटने के लिए तैयार हैं?
-
누샤 오벨: 그녀가 포츠담의 문제들을 해결할 수 있을까?
-
努莎·奧貝爾:她能否應對波茨坦面臨的問題?
-
Нооша Аубель: Сможет ли она справиться с проблемами Потсдама?
-
Нооша Аубель: Чи зможе вона впоратися з проблемами Потсдама?
-
Noosha Aubel: Is she up to the task of tackling Potsdam’s problems?
-
Stocks mostly rise tracking earnings, US-Iran hopes
-
Alarm at German airport after drone found near Ukrainian plane, mid-air incident
-
Pakistan team reaches base camp with body of renowned climber killed in avalanche
-
Salah arrives in Turkey for Trabzonspor talks
-
Ceuta warns of 'unsustainable' situation for child migrants after influx
-
Embattled FIFA chief Infantino holds emergency talks with directors
-
SpaceX rocket stage believed to have slammed into Moon
-
Russian barrage on Kyiv kills 17 as Ukraine fails to down single missile
-
India monsoon floods, landslides kill more than 100 since July: officials
-
'Lost': Migrants despair after Britain expels them back to France
-
South Korea pro baseball league cancels games over heatwave
-
Cathay Pacific's profit soars 71% despite Iran war driving up fuel costs
-
Taiwan probes 17 China-funded firms over high-tech talent poaching
-
Russian barrage on Ukraine kills 15, wounds dozens more
-
Trump warns Iran to open Hormuz or get 'hit very hard'
-
South Korea police raid Starbucks HQ over 'Tank Day' fiasco
-
Factories shed workers in Bangladesh garment sector
-
Tech back in fashion as Asian markets extend rebound
RFK Jr panel votes against ingredient targeted by anti-vaxxers
A newly appointed US medical panel voted Thursday to oppose the use of a vaccine ingredient long targeted by Health Secretary Robert F. Kennedy Jr. over debunked claims it causes autism.
Thimerosal, a preservative that prevents bacterial and fungal contamination in multidose vials, has been extensively studied, with authorities including the World Health Organization finding no evidence of harm beyond minor injection-site reactions.
Though thimerosal is now rarely used in US vaccines, its inclusion on the Advisory Committee on Immunization Practices' agenda alarmed experts, who say the move has effectively embedded anti-vaccine talking points into national policy.
Kennedy -- who spent decades spreading vaccine misinformation before becoming President Donald Trump's top health official -- abruptly fired all 17 ACIP members earlier this month, accusing them of conflicts of interest.
Across three votes, his new handpicked panelists recommended that thimerosal be removed from influenza vaccines for children, pregnant women and finally all adults.
Cody Meissner, a professor of pediatrics at Dartmouth University and the lone voice of dissent, said: "The risk from influenza is so much greater than the nonexistent risk as far as we know from thimerosal," adding that he was worried about the decision's global impact.
Although 96 percent of US flu vaccines in the 2024-2025 season did not contain thimerosal, the preservative remains important globally, particularly in multidose vials that must be punctured repeatedly, raising the risk of contamination.
Thimerosal contains an artificial form of mercury called ethylmercury that is cleared from the body far more quickly than the form of the substance found in nature.
US manufacturers voluntarily removed it from most pediatric vaccines in 2001.
- 'Platform for anti-vaccine talking points' -
"The fact that it's being brought up again -- something that's already been adjudicated -- shows how the ACIP is becoming a platform for anti-vaccine talking points to come back to life long after most of us thought they'd been put to rest," Amesh Adalja, an infectious disease specialist at Johns Hopkins University, told AFP.
Ahead of the vote, Lyn Redwood, a nurse and former leader of the anti-vaccine group Children's Health Defense, which Kennedy once chaired, was invited to present arguments against thimerosal.
A previous version of her slideshow, which was posted online before the meeting, was removed without explanation after it was found to contain a fabricated citation, likely the result of an AI hallucination.
The Centers for Disease Control and Prevention had prepared a rebuttal to Redwood's presentation, but it was mysteriously removed from the meeting website.
Robert Malone, a new panel member known for spreading misinformation during the Covid-19 pandemic, including promoting the antiparastic drug ivermectin to treat the virus, later said the CDC document had not been approved by the Office of the Secretary.
Earlier in the meeting, the same panel voted to recommend a new antibody treatment against RSV, a common respiratory illness and the leading cause of infant hospitalization in the United States.
Clesrovimab, recently approved by the Food and Drug Administration, is administered as a single shot to newborns and young babies entering their first respiratory syncytial virus season.
Marketed as Enflonsia by Merck, it was shown in clinical trials to significantly reduce RSV infections and hospitalizations among infants.
X.M.Francisco--PC